New potential inhibitors of mTOR: a computational investigation integrating molecular docking, virtual screening and molecular dynamics simulation

Abstract

The mTOR (mammalian or mechanistic Target Of Rapamycin), a complex metabolic pathway that involves multiple steps and regulators, is a major human metabolic pathway responsible for cell growth control in response to multiple factors and that is dysregulated in various types of cancer. The classical inhibition of the mTOR pathway is performed by rapamycin and its analogs (rapalogs). Considering that rapamycin binds to an allosteric site and performs a crucial role in the inhibition of the mTOR complex without causing the deleterious side effects common to ATP-competitive inhibitors, we employ ligand-based drug design strategies, such as virtual screening methodology, computational determination of ADME/Tox properties of selected molecules, and molecular dynamics in order to select molecules with the potential to become non-ATP-competitive inhibitors of the mTOR enzymatic complex. Our findings suggest five novel potential mTOR inhibitors, with similar or better properties than the classic inhibitor complex, rapamycin.

Keywords:

• mTOR
• no ATP-competitive inhibitors
• molecular docking simulation
• virtual screening
• molecular dynamics

Acknowledgement

We gratefully acknowledge the Hydrogen Bonds script from Luis Fernando Saraiva Macedo Timmers, Thiago Lipinski Paes and Walter Ritzel Paixão-Côrtes from LABIO-PUCRS.

Disclosure statement

No potential conflict of interest was reported by the authors.